Inhibitor deacetylase histone AR-42 tăng cường miễn dịch chống khối u trung gian CD8+ T tế bào đặc hiệu E7 được kích thích bởi tiêm chủng DNA HPV điều trị

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: A Cancer J Clin 61:69–90 Society AC (2012) Detailed guide: cervical cancer. American Cancer Society, Atlanta, GA Spee P, Neefjes J (1997) TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27:2441–2449 Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5:103–114 Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669–678 Center SKCC (2009) A pilot study of pnGVL4a-CRT/E7 (Detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD Center SKCC (2011) Safety study of HPV DNA vaccine to treat head and neck cancer patients. ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD Wade PA (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 10:693–698 Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84–100 Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12:482–491 Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971–984 Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497–1511 Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784 Kulp SK, Chen CS, Wang DS, Chen CY (2006) Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 12:5199–5206 Lu Q, Yang YT, Chen CS, Davis M, Byrd JC, Etherton MR, Umar A (2004) Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 47:467–474 Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S et al (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res 13:2318–2322 Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL, Weng JR (2011) Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol 68:489–496 Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC (2010) A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One 5:e12417 Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL et al (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46:1119–1130 Vanniasinkam T, Ertl H, Tang Q (2006) Trichostatin-A enhances adaptive immune responses to DNA vaccination. J Clin Virol: Off Publ Pan Am Soc Clin Virol 36:292–297 Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF, Wang CC, Yen MC, Lin CC (2010) An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther 17:203–211 Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017–7024 Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21–26 Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC (2003) CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10:1311–1320 Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC (2000) Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7:726–733 Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723–2730 Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M (1999) Calreticulin: one protein, one gene, many functions. Biochem J 344(Pt 2):281–292 Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698–3703 Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC (2000) Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60:1035–1042 Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, Chen CS (2008) OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68:3999–4009 Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR et al (2010) The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 5:e10941 Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen CS, Lairmore MD (2011) Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res 35:1491–1497 Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT (2007) The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 120:1795–1802 Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP (2009) Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac: Off Publ Int Assoc Study of Lung Cancer 4:161–166 Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D (2012) Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol 127:579–586 Nagumo T, Takaoka S, Yoshiba S, Ohashi M, Shirota T, Hatori M, Isobe T, Tachikawa T, Shintani S (2009) Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol 45:766–770 Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, Denk H (2010) Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 9:49 Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF et al (2010) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemother Pharmacol 66:1131–1140 Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC (2008) Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 26:351–360 Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242–2249 Huang B, Mao CP, Peng S, He L, Hung CF, Wu TC (2007) Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 25:7824–7831 Center MDAC (2006) A phase II study of depsipeptide, a histone deacetylase inhibitor, in relapsed or refractory mantle cell or diffuse large cell non-Hodgkin’s lymphoma. ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD. Accessed 10 August 2012 Therapeutics C (2008) A phase I study to evaluate the safety and tolerability of the histone deacetylase inhibitor, CHR-3996, in patients with advanced solid tumours. ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD. Accessed 10 August 2012 Center SKCC (2005) A phase I/II clinical trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD Hofmeister C (2010) Phase I study of AR-42 in relapsed myeloma, chronic lymphocytic leukemia, and lymphoma. ClinicalTrials.gov. National Library of Medicine (US), Bethesda, MD. Accessed 10 August 2012 Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122–1128